Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)
CNY 8.44
(-0.12%)
CNY 8.44
(-0.12%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.6 Billion CNY | -2.28% |
| 2022 | 1.64 Billion CNY | 15.23% |
| 2021 | 1.42 Billion CNY | -4.25% |
| 2020 | 1.49 Billion CNY | 10.26% |
| 2019 | 1.35 Billion CNY | 16.38% |
| 2018 | 1.16 Billion CNY | 21.42% |
| 2017 | 958.15 Million CNY | 25.46% |
| 2016 | 763.68 Million CNY | 31.73% |
| 2015 | 579.74 Million CNY | 13.51% |
| 2014 | 510.72 Million CNY | 15.33% |
| 2013 | 442.84 Million CNY | 22.9% |
| 2012 | 360.32 Million CNY | 23.67% |
| 2011 | 291.36 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 294.46 Million CNY | -13.9% |
| 2024 Q1 | 340.43 Million CNY | 5.32% |
| 2024 Q2 | 341.98 Million CNY | 0.46% |
| 2023 Q3 | 430.79 Million CNY | -5.88% |
| 2023 FY | 1.6 Billion CNY | -2.28% |
| 2023 Q1 | 397.91 Million CNY | -4.13% |
| 2023 Q4 | 323.23 Million CNY | -24.97% |
| 2023 Q2 | 457.72 Million CNY | 15.03% |
| 2022 Q2 | 428.81 Million CNY | 6.58% |
| 2022 Q3 | 401.06 Million CNY | -6.47% |
| 2022 Q4 | 415.05 Million CNY | 3.49% |
| 2022 FY | 1.64 Billion CNY | 15.23% |
| 2022 Q1 | 402.33 Million CNY | 10.66% |
| 2021 Q1 | 395.13 Million CNY | 2.9% |
| 2021 Q2 | 380.71 Million CNY | -3.65% |
| 2021 Q4 | 363.56 Million CNY | 25.31% |
| 2021 FY | 1.42 Billion CNY | -4.25% |
| 2021 Q3 | 290.13 Million CNY | -23.79% |
| 2020 Q3 | 292.55 Million CNY | -34.87% |
| 2020 Q1 | 367.2 Million CNY | -5.13% |
| 2020 Q4 | 383.99 Million CNY | 31.25% |
| 2020 FY | 1.49 Billion CNY | 10.26% |
| 2020 Q2 | 449.19 Million CNY | 22.33% |
| 2019 Q1 | 295.2 Million CNY | 8.9% |
| 2019 Q4 | 387.07 Million CNY | 3.33% |
| 2019 FY | 1.35 Billion CNY | 16.38% |
| 2019 Q3 | 374.6 Million CNY | 26.06% |
| 2019 Q2 | 297.15 Million CNY | 0.66% |
| 2018 Q3 | 270.48 Million CNY | -14.6% |
| 2018 FY | 1.16 Billion CNY | 21.42% |
| 2018 Q4 | 271.08 Million CNY | 0.22% |
| 2018 Q2 | 316.73 Million CNY | 3.81% |
| 2018 Q1 | 305.12 Million CNY | 19.85% |
| 2017 Q3 | 229.04 Million CNY | -6.05% |
| 2017 Q2 | 243.8 Million CNY | 5.68% |
| 2017 Q4 | 254.59 Million CNY | 11.15% |
| 2017 FY | 958.15 Million CNY | 25.46% |
| 2017 Q1 | 230.69 Million CNY | 13.99% |
| 2016 FY | 763.68 Million CNY | 31.73% |
| 2016 Q1 | 159.9 Million CNY | 11.11% |
| 2016 Q3 | 197.74 Million CNY | -2.9% |
| 2016 Q4 | 202.37 Million CNY | 2.34% |
| 2016 Q2 | 203.66 Million CNY | 27.37% |
| 2015 Q2 | 142.25 Million CNY | 6.23% |
| 2015 Q4 | 143.91 Million CNY | -9.86% |
| 2015 Q3 | 159.65 Million CNY | 12.23% |
| 2015 Q1 | 133.91 Million CNY | -1.19% |
| 2015 FY | 579.74 Million CNY | 13.51% |
| 2014 FY | 510.72 Million CNY | 15.33% |
| 2014 Q1 | 114.32 Million CNY | 0.0% |
| 2014 Q4 | 135.53 Million CNY | 0.0% |
| 2013 FY | 442.84 Million CNY | 22.9% |
| 2012 FY | 360.32 Million CNY | 23.67% |
| 2011 FY | 291.36 Million CNY | 0.0% |